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Summary 
Background Post-mastectomy chest-wall radiotherapy (PMRT) for 'intermediate' risk breast cancer is 
controversial.  BIG2-04 MRC EORTC SUPREMO (ISRCTN61145589) is an international phase III 
randomised controlled trial assessing the role of PMRT in this patient group. The primary endpoint of 
SUPREMO is overall survival at 10 years, with quality of life (QOL) a secondary endpoint. The QOL 
sub-study examined the effects of PMRT on primary outcomes: global QOL, fatigue, physical 
function, chest-wall, arm symptoms, body image, anxiety/depression at 1, 2, 5 and 10 years. Here 
we report QOL results at 2 years.  
 
Methods SUPREMO randomised women post mastectomy and axillary surgery to receive chest-wall 
radiotherapy or not (1:1 ratio). All UK centres participated in the QOL sub-study. Patients completed 
the EORTC QLQ-C30 and BR23 questionnaires, Body Image Scale, Hospital Anxiety and Depression 
Scale (HADS) and EQ-5D-3L pre-randomisation, 1 and 2 years.  Repeated mixed-effects methods 
were employed, with baseline score, time and age as covariates. Exploratory analyses evaluated 
whether systemic treatments, axillary and reconstructive surgery influenced the QOL outcomes.   
 
Findings  
SUPREMO enrolled 1688 patients internationally between 2007-13. Of the 1258 UK patients 989 
(79%) consented to participate  in the QOL sub-study, 95·7% returned the baseline, 83·1% year 1 and 
77·9% year 2 questionnaires. Patients receiving PMRT reported worse chest-wall symptoms 
(p=0·0161), with an improvement between years 1 and 2. Chemotherapy was associated with less 
improvement without interaction with radiotherapy.  No significant between-group differences were 
observed for arm symptoms, body image, fatigue, pain, overall QOL, physical functioning or HADS 
scores. Younger patients reported worse body image problems (p=0·007) and anxiety (p=0·0001). 
 
Interpretation PMRT led to more local symptoms up to 2 years post-randomisation, but the 
difference is small, and there was no impact on other pre-specified QOL domains.   
 
Funding Medical Research Council, European Organisation for Research and Treatment of Cancer, 
Cancer Australia, Dutch Cancer Society, Trustees of Hong Kong Shanghai Banking Corporation. 
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Research in Context 
Evidence before this study 
Adjuvant chest-wall irradiation after mastectomy remains a core effective element in the loco-
regional management of early breast cancer reducing loco-regional recurrence and breast cancer 
mortality. While the evidence base for post-mastectomy radiotherapy (PMRT) in patients with 4 or 
more involved axillary nodes is robust, its role in 'intermediate' risk patients with 1-3 involved nodes 
is controversial and practices vary. The Oxford overview in 2014 shows an advantage from PMRT in 
patients with 1-3 positive nodes. However, the generalisability of historical trials with different 
standards of surgery, radiotherapy and systemic therapy remains uncertain.  Benefits in survival 
needs to be balanced against risk of loco-regional and cardio-pulmonary toxicity, particularly in 
conjunction with potentially cardiotoxic anthracyclines and trastuzumab. The recent American 
Society of Clinical Oncology guidelines on the use of PMRT emphasizes the importance of evaluating 
the risk-benefit ratio, but the data is derived from patients treated several decades previously and 
only a limited number of small studies looked at patient-reported outcomes, such as symptoms and 
quality of life. 
Added value of this study 
Our study uniquely investigated the impact of adjuvant PMRT on quality of life in a randomised trial 
ŝŶĐůƵĚŝŶŐĂůĂƌŐĞ ?ǁĞůůĐŚĂƌĂĐƚĞƌŝƐĞĚƉŽƉƵůĂƚŝŽŶŽĨh<ƉĂƚŝĞŶƚƐǁŝƚŚ ?ŝŶƚĞƌŵĞĚŝĂƚĞ-ƌŝƐŬ ?ďƌĞĂƐƚĐĂŶĐĞƌ 
post-mastectomy. At 2 years PMRT was associated with worse self-reported local symptoms (pain, 
ƐǁĞůůŝŶŐ ?ƐŬŝŶƉƌŽďůĞŵƐŝŶƚŚĞ “ĂƌĞĂŽĨƚŚĞĂĨĨĞĐƚĞĚďƌĞĂƐƚ ? ?ŝŶĐŽŵƉĂƌŝƐŽŶǁŝƚŚŶŽƌĂĚŝŽƚŚĞƌĂƉǇ ?ďƵƚ
the difference is small, unlikely to be of clinical significance and the symptoms improved over time. 
There were no differences in arm symptoms, body image, fatigue, pain, overall QOL, physical 
functioning anxiety or depression. 
Implications of all the available evidence 
The impact on PMRT on 10 year survival, the primary endpoint of the main SUPREMO trial, will not 
be known before 2023. In the meantime, both options of administering or omitting PMRT are 
legitimate for patients in the intermediate risk category (1-3 positive lymph nodes). Our data will 
inform shared decision-making (as recommended in the recent North American guidelines) and put 
patients in a better position to make an informed value judgment on what they consider relevant for 
their situation given the data on the patient-reported symptoms and QOL domains presented in this 
report. Both physicians and patients may be helped when weighing up the individual estimates of 
possible benefits of radiotherapy against the impact of PMRT on toxicity and quality of life. 
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Introduction 
Current multimodality treatment for breast cancer has improved survival rates. 1 Avoiding 
overtreatment and balancing the treatment burden against benefit has become an important 
research field. Examples of trials investigating selective omission of radiotherapy or chemotherapy 
have recently been reported. 2,3  While the impact of mastectomy and chemotherapy on quality of 
life has been well documented the additional effect of adjuvant radiotherapy following mastectomy 
is unclear. Chest wall pain, fatigue, anxiety about recurrence and depressive symptoms can all hold 
back recovery and return to normal activities of daily living. 4 
Adjuvant chest wall irradiation after mastectomy remains a core and highly effective element in the 
loco-regional management of early breast cancer reducing loco-regional recurrence and breast 
cancer mortality. While the evidence base for post-mastectomy radiotherapy (PMRT) in patients 
with 4 or more involved axillary nodes is robust, its role in 'intermediate' risk patients with 1-3 
involved nodes is controversial and practice and guidelines vary.5 The Oxford overview in 2014 
shows an advantage from PMRT which included at least the chest wall in the target volume in 
patients with both 1-3 and 4 or more positive nodes.6 However, the generalisability of historical 
trials with different standards of surgery, radiotherapy and systemic therapy remains uncertain, 
especially as contemporary survival rates are much higher than in the studies included in the 
overview.  Potential benefits in survival needs to be balanced against risk of loco-regional and 
cardio-pulmonary toxicity, particularly in conjunction with potentially cardiotoxic anthracyclines and 
trastuzumab. A recent update by the American Society of Clinical Oncology on the use of post-
mastectomy radiotherapy emphasizes the importance of evaluating the risk-benefit ratio, 
particularly in patients with a low risk of local failure.7 The benefit of PMRT relies on estimates of 
recurrence risk, modulated by biological tumour characteristics, weighed against the negative 
impact of PMRT on the risks of late toxicity (e.g. cardiac toxicity from radiotherapy may be increased 
by the combination with systemic therapy).8 The data currently available on these modulating 
effects is derived from patients treated several decades previously. 
Selective use of post-mastectomy radiotherapy is being evaluated in the BIG 2.04 MRC/EORTC 
SUPREMO trial (ISRCTN61145589), which assesses the effects of adjuvant chest wall radiotherapy 
without axillary irradiation ŝŶ ƉĂƚŝĞŶƚƐ ǁŝƚŚ  ?ŝŶƚĞƌŵĞĚŝĂƚĞ ƌŝƐŬ ?early breast cancer who have 
undergone mastectomy and adequate systemic therapy following contemporary guidelines for all 
treatment modalities. This is the largest randomised trial to date to assess the role of PMRT in this 
subset of patients. The endpoints have been previously described. 9 In brief, the primary endpoint of 
the trial is overall survival at 10 years. Secondary end points include various breast cancer 
recurrence endpoints, toxicity, acute and late morbidity (cardiac morbidity and mortality) and 
quality of life. Sub-studies include the TRANS-SUPREMO seeking molecular markers of 
radiosensitivity, a cardiac sub-study, and for UK patients only Quality of Life (QOL) assessment and 
Health Economics evaluation. These sub-studies will provide an important high-quality evidence 
base on the balance of potential benefits and treatment burden, to support patients and health care 
professionals during shared decision-making. 
The long-term impact of breast cancer and its treatment on everyday life has been identified as a 
critical knowledge gap and a key priority for breast cancer research 10. For radiotherapy, there is a 
limited information on treatment impact.  A small number of trials have investigated self-reported 
breast, arm, and shoulder symptoms, functional outcomes and quality of life after radiotherapy, 
predominantly in breast conserving therapy11-13. Patients usually report transient and short-term 
effects of radiotherapy, with relatively limited effect on overall quality of life 14,15 .  
No comprehensive QOL data exists in patients having PMRT and only a few studies have compared 
patient-reported outcomes following breast-conserving surgery versus mastectomy with and 
without reconstruction. Recent introduction of oncoplastic surgical techniques is expected to have 
an impact on post-treatment morbidity and patient satisfaction with body image16-19. There is a 
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dearth of level 1 evidence assessing the impact of adjuvant post-mastectomy radiotherapy on QOL 
of patients who have undergone reconstruction.  
The SUPREMO QOL sub-study aimed to examine the effects of PMRT on several primary QOL 
outcomes (global QOL, fatigue, physical function, chest wall, shoulder and arm symptoms, body 
image, anxiety and depression) at 1, 2, 5, and 10 years post treatment. Here we report the 2-year 
results. To our knowledge, this is the first study looking at the impact of adjuvant radiotherapy on 
QOL in large randomised trial confined to patients treated by mastectomy for early breast cancer 
(including patients undergoing breast reconstruction). 
Methods 
Study design and Participants 
SUPREMO was an open label parallel randomized trial. The full eligibility, exclusion criteria and trial 
procedures are described in the trial protocol provided in the supplementary web material. Briefly, 
patients were eligible if they had undergone mastectomy for unilateral breast cancer, and an axillary 
staging procedure with axillary lymph node dissection, iĨŶŽĚĞƉŽƐŝƚŝǀĞ ?WĂƚŝĞŶƚƐǁŝƚŚ ?ŝŶƚĞƌŵĞĚŝĂƚĞ
ƌŝƐŬ ? breast cancer were eligible, defined as pT1-2N1, pT3N0 and pT2N0, if also grade III and/or with 
lympho-vascular invasion on histology. All patients had to receive adequate systemic therapy 
following contemporary guidelines depending on patient and tumour characteristics. If this included 
chemotherapy, treatment regimes containing at least 4 cycles of anthracyclines were recommended. 
Adjuvant trastuzumab was given according to local practice. In 2011 the eligibility criteria were 
widened, following a protocol amendment approved by the Ethics Committee, to include neo-
adjuvant chemotherapy.  For patients randomized to chest wall radiotherapy, radiation was given 
after the chemotherapy (when given). Radiotherapy treatment consisted of chest wall radiation to a 
total dose of 50 Gy in 25 daily fractions of 2 Gy over 5 weeks. Other permitted radiobiologically 
equivalent schedules included 45 Gy in 20 fractions over 4 weeks, and 40 Gy in 15 fractions over 3 
weeks. Guidelines on treatment planning and set up were given, and there was a radiotherapy 
quality assurance programme in the trial. The use of bolus was permitted and had to be pre-
specified per centre. Axillary irradiation was not permitted, but medial peri-clavicular and/or internal 
mammary chain irradiation was permitted according to local policy of the centres. Boost radiation 
was not permitted.  Surgery, systemic therapy and pathology were also subject to pre-specified 
quality assurance. Additional recorded data included cardiovascular risk factors, radiotherapy 
cardiac and lung exposure parameters, systemic therapy (type, doses, dates) and any reconstructive 
surgery (type, immediate or delayed). 
Randomisation and masking 
Consenting patients were randomized post-operatively to either chest-wall radiotherapy or no 
chest-wall radiotherapy (1:1 ratio). Patients were randomised by permuted blocks with the block 
length being varied randomly to minimise the effect of entry bias.  Stratification was by treatment 
centre due to possible between centre differences in the manner in which radiotherapy is given.  
Randomisation was performed via a telephone call to The Information and Statistical Division (ISD) 
at National Services Scotland. 
Procedures 
Galina to add 
QOL sub-study 
All patients eligible for SUPREMO from UK centres were invited to participate in the QOL study. 
Patients who consented completed a questionnaire booklet in the clinic before randomisation. 
Completed bŽŽŬůĞƚƐǁĞƌĞ ƐĞŶƚ ƚŽ ƚŚĞ ƚƌŝĂů ?Ɛ ŽĨĨŝĐĞ ĂŶĚ Ɛubsequent questionnaires were posted to 
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patients at 12 and 24 months ďǇƚŚĞƚƌŝĂů ?ƐŽĨĨŝĐĞ. If the baseline questionnaire was not returned to 
the trial ?s office further questionnaires could not be sent, as patients ? names and addresses were not 
available to the trial co-ordinator. Reminders were sent to the hospitals where baseline 
questionnaires were overdue. No reminders were sent to patients at 12 and 24 months. 
QOL was assessed using several well-validated questionnaires. 
EORTC QLQ-C30 (version 3·0) and the breast module QLQ-BR23 (version 1·0). The QLQ-C30  
consists of 30 questions addressing 5 functional scales (cognitive, emotional, physical, social, and 
role), 9 symptom scales (appetite loss, constipation, diarrhoea, dyspnoea, fatigue, financial 
difficulties, insomnia, nausea and vomiting, and pain), and one Global Health Status/QOL scale20. The 
EORTC QLQ-BR23  focuses on breast cancer specific issues and includes 23 questions addressing 4 
functional: body image, future perspective, sexual enjoyment, and sexual functioning and 4 
symptom scales: arm symptoms (swelling in arm or hand, arm or shoulder pain, and difficulty raising 
the arm), breast/chest wall symptoms (pain, swelling, oversensitivity, and skin problems in the area 
of the affected breast), systemic therapy side-effects, and upset by hair loss21. All scores for the 
EORTC QLQ-C30 and EORTC QLQ-BR23 were transformed to a scale from 0 to 100. Higher scores on 
the functional scales and Global QOL represent a superior level of functioning and better QOL, 
whereas higher scores in the symptom scales or items represent worse symptoms. 
The Body Image Scale (BIS) is a 10-item scale designed specifically for use with cancer patients to 
assess aspects of attractiveness, sexual attractiveness and feelings or satisfaction with appearance.  
Scores were graded 0-3 and summed to produce a single score, where a higher score indicated more 
problems (score range from 0 to 30)22. 
Hospital Anxiety and Depression Scale (HADS) is a 14-item instrument with two sub-scales for 
anxiety and depression23. Scores range from 0 to 21 on each scale, with higher scores indicating 
more distress. Scores above 11 suggest probable cases of anxiety or depressive illness, and scores 
between 8 and 10 indicate borderline cases. A combined score of 19 or above is considered 
indicative of psychological distress. 
EQ-5D-3L questionnaire measures health status across five domains: mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression. Respondents specify whether they have no 
problems, some problems or severe problems within each domain, on the day of response. These 
EQ-5D-3L health states descriptions are converted into a single summary index (range from 0 to 1) 
by attaching a value to each of the levels in each dimension. As is standard practice, these values 
were obtained from a large UK population study using a choice-based method of valuation. 24 The 
resulting summary score, or utility value, can then be used directly in the cost-utility analysis.  
Outcomes 
Statistical analysis 
Sample size for the SUPREMO QOL study was considered as a problem of estimation rather than a 
significance testing. With 200 evaluable patients per group the proportion of patients exhibiting a 
particular side-effect or specified degree of morbidity in a QOL domain could be estimated with a 
standard error of 3·5% or less. The corresponding difference between the groups could be estimated 
with a standard error of 5% or less.  However, as there is usually a significant attrition over time, in 
order to have sufficient numbers by 10 years a target of 800 patients was set. The total sample size 
of SUPREMO was reduced during the course of the trial, following a protocol amendment approved 
by the ethics committee, from 3500 to 1600 but this did not affect the QOL sub-study sample. 
In order to maintain the Normality of the residuals, the difference from baseline to each subsequent 
questionnaire was calculated for each scale. Repeated analysis of covariance was conducted using 
PROC MIXED, to allow for observations that are missing at random. Time and treatment allocation 
interactions were tested for each scale but are to be reported where statistically significant. Baseline 
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scores are included in each model as a covariate. As the QOL study was not originally powered for 
hypothesis testing, p-values are only included for illustration. However, the treatment with 
radiotherapy was our primary outcome, and we will discuss any results that have a p-ǀĂůƵĞŽĨч ? ? ? ?
with this variable. Due to the large number of models, clinical variables will only be discussed if they 
exceed the more conservative threshold value of 0.01. 
The principal analysis modelled the change in score in the pre-specified QOL outcomes (global QOL, 
fatigue, physical function, chest wall, shoulder and arm symptoms, body image, anxiety and 
depression) by time of follow up, age group (<45, 45-54, 55- ? ? ?ш ? ? ?, baseline score and treatment 
(± radiotherapy).  
As almost all patients received some form of systemic therapy and some underwent breast 
reconstructive surgery, secondary exploratory analyses were performed to evaluate whether these 
treatments influenced the QOL outcome measures. The secondary analysis included clinical 
covariates also considered to have an impact on QOL (extent of axillary surgery, early breast 
reconstruction, adjuvant chemotherapy, adjuvant hormonal therapy and trastuzumab). This was 
performed by creating a basic model of age group, time and baseline score, then adding the clinical 
variables in turn to create a model of best fit. This process was then repeated until no variables 
added significantly to the model. The radiotherapy variable was then added to the best fit model. 
Only patients with complete data for all clinical variables were included in this modelling. 
All analyses were on an intention to treat basis. The analysis was generated using version 9·4 of the 
SAS System for Windows (www.sas.com Copyright © 2012 SAS Institute Inc. SAS and all other SAS 
Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., 
Cary, NC, USA.)  
This study is registered [as an International Standard Randomised Controlled Trial, number 
ISRCTN61145589. 
Role of Funding Source  
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author and the joint senior authors had 
full access to all data in the study and had final responsibility for the decision to submit for 
publication. 
 
Results 
Between April 2007-May 2013 the trial recruited 1688 patients internationally, of which 1258 were 
from 111 UK centres and eligible for the QOL study. Ten UK centres did not include any of their 66 
patients in the QOL study. A total of 989 (79%) UK patients consented to participate, of them 947 
patients (95·7%) returned the baseline questionnaires (476/502 94·8% in the control and 471/487 
96·7% in the radiotherapy arm). Due to the practical arrangements for the QOL data collection, 
questionnaires for years 1 and 2 could be sent only to patients who returned the baseline 
questionnaire. We have not formally recorded reasons for declining as according to the Ethics 
Committee approved patient information sheets, patients were not obliged to provide such reasons. 
The patients from UK who declined participation or did not return the baseline questionnaires were 
older (n=311 mean age 57.7 years, SD 11.9) than those who consented and returned the baseline 
questionnaire (n=947 mean age 56.1 years, SD=11.0; p=0.02). Comparing the age of QOL study 
participants with the rest of the main trial (UK patients not participating in QOL study and all 
patients from other countries) did not show an age difference (n=741 mean age 55.6 years SD 11.6, 
p=0.34).  In order to check further for potential bias in patient selection for the QOL sub-study, we 
compared the clinical characteristics of the patients completing the QOL sub-study with those of the 
patients in the main trial in Table 1 (see below). 
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Good patient compliance was achieved with the completion of QOL measures: at year 1 388/466 
83·3% in the control group and 388/467 83·1% in the radiotherapy group; at year 2 (350/463 75·6% 
and 367/457 80·3% respectively. A slightly better compliance was observed in the radiotherapy arm 
at baseline and year 2 (Figure 1).  
Patient characteristics 
Patients demographic, clinico-pathological characteristics and treatment details are shown in Table 
1. Two-thirds of patients had T2 tumours, slightly over half were Grade 3, over 78% were ductal 
carcinomas, approximately 20% were Estrogen/Progesteron Receptor negative, and 30% Her2 
positive. Only a small proportion of just over 10% had immediate reconstruction, and 10% late 
reconstruction (by 2 years). A further review of the type of breast reconstruction suggested more 
frequent autologous reconstructions in the radiotherapy group, whereas there were more 
reconstructions with an implant/expander in the control group (see supplementary file).  This trend 
was observed for both the immediate and the late reconstructions.  Over 80% of participants had 
adjuvant chemotherapy, 20% trastuzumab and over 70% endocrine therapy. No differences are 
observed between the QOL participants and the full trial.  
The majority of patients in the radiotherapy group of the QOL study received 40 Gy in 15 fractions 
(69%), with the remaining patients equally divided between 50 Gy in 25 fractions (11%), 45 Gy in 20 
fractions (10%) and other/unknown (10%). In the main trial, a smaller proportion of 52% received 40 
Gy in 15 fractions, a larger proportion of 27% had 50 Gy in 25 fractions, 7% had 45 Gy in 20 fractions 
and 15% - other/unknown. The dose for all EORTC centres was 50 Gy in 25 fractions. 
Baseline and follow-up QOL scores are shown in Table 2. Baseline scores were reported following 
surgery and prior to randomisation. Of note, patients reported relative impairment in global QOL 
with a mean score of 60 (100 is excellent), a high level of fatigue (mean of 40, where 100 is greatest 
degree of fatigue), insomnia (mean of 36-37; 100 is worse) and a degree of arm symptoms, chest 
wall symptoms and pain (in the range of 17 to 24; 100 is worst symptom).  
Pre-specified primary QOL outcomes 
Table 3 presents the results from mixed-effects models analysis of pre-specified primary QOL 
outcomes and pain (a pre-specified secondary QOL outcome).  The tested clinical variables are 
included in Table 3 where they were found to have a significant effect (p<0.01) on either the 
radiotherapy treatment or on changes over time. Such effects were found for adjuvant 
chemotherapy and immediate breast reconstruction but not for extent of axillary surgery, adjuvant 
hormonotherapy or trastuzumab. 
Chest wall symptoms were worse in the group receiving radiotherapy (estimate of effect 2·17; 95% 
Confidence Interval (CI) 0·40, 3·94; p=0·016). There was an improvement between years 1 and 2 
(visit effect -1.34; 95% CI -2·36, -0·31; p=0·010), but the improvement was smaller in the 
radiotherapy group (Figure 2a). Of the clinical factors the use of chemotherapy was associated with 
less improvement in chest wall symptoms but there was no interaction with radiotherapy, 
suggesting an additive effect of chemotherapy (Figure 2a).  There was a borderline age effect, with 
patients <45 years having worse chest wall symptoms than those ш ? ? years (estimate of effect 4·49; 
95% CI 0·59, 8·39; p=0·02). 
Arm problems did not differ significantly according to radiotherapy treatment (Figure 2b), they 
improved in both group between years 1 and 2, with a greater improvement in older patients (data 
not shown). When clinical variables were included the effect of age was no longer apparent. 
However, chemotherapy had an effect with patients receiving chemotherapy showing less 
improvement of arm symptoms over time, suggesting that chemotherapy and age were 
confounders. Significantly more patients who received chemotherapy were in the younger age group 
(97% of patients <45 years, 97% in 45-54 years, 85% in 55-69 years, 37% in ш ? ? years groups, P < 
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0·0001). Contrary to the clinical expectations, the extent of axillary surgery did not have an effect on 
arm/shoulder symptoms scores (models not shown). 
Despite the observed differences in chest wall symptoms patients reported relatively few body 
image problems with improvement between years 1 and 2. Some age effect was observed with 
patients <45 years old reporting more concerns about their body image in comparison with patients 
ш ? ? years old (estimate of effect 1·96; 95% CI 0·53, 3·39; p=0·007). 
The overall QOL of patients was not affected by radiotherapy treatment. Furthermore, improvement 
in overall quality of life was observed between baseline and year 1 with further but smaller 
improvement by year 2 (Figure 2c).  
Physical function was not affected by treatment and no change was observed over time (Figure 2d). 
As expected there was an age affect with the younger age group reporting better overall physical 
functioning (Table 3). 
Patients reported high baseline level of fatigue, likely due to the preceding surgery. Significant 
improvement between year 1 and 2 was observed. Immediate reconstruction had a borderline 
impact on the change scores at year 1 (estimate of effect 5·32; 95% CI 0·94, 9·69; p=0·017), possibly 
related to slower recovery from the operation (Figure 2e), but without detectable differences in 
overall QOL or body image. 
No group differences were seen in HADS-Anxiety and HADS-Depressions scores. Women younger 
than 70 reported higher levels of Anxiety with improvement from baseline to  year 1 and to year 2  
in both groups. 
Pre-specified secondary QOL outcomes 
An interesting pattern in self-reporting of general pain was observed. The mean score at baseline 
was just over 20 in both groups, but without any improvement from baseline to year 1 or year 2 
independent of randomisation arm, which is at odds with some of the findings for the primary 
outcomes (global QOL, fatigue, chest-wall symptoms, body image and anxiety) where we observed 
an improvement from baseline. We investigated the potential impact of systemic treatments. 
Borderline effects were found for use of trastuzumab (P=0·06) and chemotherapy (P=0·08), possibly 
associated with the use of taxanes. No effect was found for endocrine therapy (none vs tamoxifen vs 
aromatase inhibitors).  
No between-group differences were observed for nausea/vomiting, sexual, role and social functions. 
Gradual improvement over time was observed without any effect of treatments. Role function and 
social function showing the biggest numerical improvement over time, in year 1 with continued 
improvement in year 2. Patients having radiotherapy reported larger improvements in their social 
function in comparison with those who did not (details in online Appendix). Patients reported very 
low scores on sexual functioning (mean of 11 out of 100) suggesting that the vast majority of 
patients are not sexually active. This is supported by the fact that only about 25% responded to the 
optional question on sexual enjoyment (Table2). 
The exploratory analysis of the other scales is in an online appendix. All remaining scales and items 
did not show any impact of radiotherapy treatment and all show improvement or stability over time.  
Discussion 
To our knowledge, this is the first study investigating the impact of adjuvant radiotherapy on quality 
of life after mastectomy in a large randomised trial including a large, well characterised population 
of UK patients ǁŝƚŚ  ?ŝŶƚĞƌŵĞĚŝĂƚĞ-ƌŝƐŬ ?ďƌĞĂƐƚĐĂŶĐĞƌ. The key finding is that PMRT was associated 
with worse local self-reported symptoms (pain, swelling, oversensitivity and skin problems in the 
 “ĂƌĞĂ ŽĨ ƚŚĞ ĂĨĨĞĐƚĞĚ ďƌĞĂƐƚ ? ? ŝŶ ĐŽŵƉĂƌŝƐŽŶ ǁŝƚŚ ŶŽ ƌĂĚŝŽƚŚĞƌĂƉǇ ? ĂůƚŚŽƵŐŚ ƚŚĞƐĞ ƐǇŵƉƚŽŵƐ
improved over time. The estimated effect is small, with a difference between the radiotherapy and 
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control group of 2·17 points; 95% CI 0·40, 3·94. To the best of our knowledge there is no available 
data on what difference in the sub-scale scores of EORTC-BR23 is clinically significant. Using a 
generic approach of 0.5 of the standard deviation to indicate minimally important difference, we 
ĐĂůĐƵůĂƚĞĚ ƚŚĞ ƐƚĂŶĚĂƌĚĚĞǀŝĂƚŝŽŶŽĨ ƚŚĞ  “ĐŚĂŶŐĞƐĐŽƌĞ ?for chest wall symptoms from baseline to 
year 1 in the control group. 25  The standard deviation was 17.3 and a score 8.65 is likely to indicate a 
clinically meaningful difference. The observed difference of 2.17 is relatively small and unlikely to be 
of clinical significance, which is of course reassuring for patients and clinicians. Persistent pain 
following breast surgery (breast conserving or mastectomy) was also reported by Gartner et al and 
was commoner after adjuvant radiotherapy and in younger women. 26 
There was no impact of radiotherapy to the chest wall on arm symptoms (axillary radiotherapy was 
prohibited in the trial), body image, overall QOL, physical function, fatigue or symptoms of anxiety or 
depression. Exploratory analyses showed that systemic chemotherapy treatment had an additive 
borderline ĞĨĨĞĐƚ ŽŶ ƉĂƚŝĞŶƚƐ ? ĐŚĞƐƚ ǁĂůů ĂŶĚ ĂƌŵƐ ƐǇŵƉƚŽŵƐ ďƵƚ ǁŝƚŚŽƵƚĂŶ ŝŶƚĞƌĂĐƚŝŽŶ ǁŝƚŚ ƚŚĞ
radiotherapy treatment. This is consistent with other studies 27.   
The use of sentinel node biopsy procedure is the current standard practice for axillary surgery. In 
SUPREMO about a quarter of patients (those with pN0 (sn) tumours) in the main and QoL sub-study 
underwent limited axillary surgery (sentinel node biopsy or nodal sampling). The extent of axillary 
surgery had no impact on any of the pre-specified QOL outcomes, including arm symptoms. This is 
perhaps an unexpected finding and could be due to lack of sensitivity of the EORTC BR23 scale 
 ?ǁŚŝĐŚŚĂƐ  ? ŝƚĞŵƐŽŶ  ?ƉĂŝŶ ŝŶĂƌŵŽƌ ƐŚŽƵůĚĞƌ ? ?  ?ƐǁŽůůĞŶĂƌŵŽƌŚĂŶĚ ?ĂŶĚ  ?ĚŝĨĨŝĐƵůƚǇ ƌĂŝƐŝŶŐǇŽƵƌ
Ăƌŵ ? ? ?The impact of radiotherapy to the axilla on arm symptoms cannot be evaluated in the 
SUPREMO trial, as this was prohibited, but this has been investigated in other trials.28  
We observed a low rate of immediate breast reconstruction (only 111 patients), this procedure was 
associated with higher fatigue levels and slower recovery in comparison with no immediate 
reconstruction but no impact on body image or the other QOL outcomes. The estimated effect of 
immediate reconstruction on fatigue was 5.32, corresponding to a small clinically meaningful 
difference29. This was an exploratory analysis and we used a generic QOL and body image 
questionnaires rather than breast-reconstruction instruments (such as BREAST-Q), which is likely less 
sensitive to specific outcomes 17.  
It should be noted that the observed levels of reconstructive surgery (either immediate or delayed 
to year 2) are low in the range of 10-13%. This likely reflects the pattern of care in the period of the 
SUPREMO trial recruitment (2006-2013) or may be due to concerns of entering patients who had 
reconstruction into a trial of radiotherapy. There appears to be a trend in using more autologous 
procedures in patients who had radiotherapy and more implants/expanders in those not receiving 
radiotherapy. Due to the small number of reconstructions, SUPREMO trial cannot provide useful 
information on the impact of radiotherapy on breast reconstruction, and further evidence is needed. 
We are collecting further information on delayed (beyond 2 years) reconstructions, which will be 
analysed at 5 and 10 years and provide valuable information on rates of breast reconstruction across 
the UK, as ǁĞůůĂƐŝƚƐŝŵƉĂĐƚŽŶƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐĂŶĚƐĂƚŝƐĨĂĐƚŝŽŶǁŝƚŚďŽĚǇŝŵĂŐĞ ? 
 
Most of the published literature relating to the impact of adjuvant radiotherapy on QOL relates to 
non-randomised studies, often of small size, which may be subject to selection bias and neither 
surgery, radiotherapy or systemic treatments were subject to pre-specified quality assurance. 
Comparisons are often difficult because of differing types of surgery, stage of disease, QOL measure 
used and time-points of QOL assessment. The studies often included both patients treated by 
mastectomy and breast conserving surgery. The START trial looked at late effects of different 
schedules of radiotherapy at 5 years and found that up to a third of women reported moderate or 
marked pain in the arm and shoulder and more than 10% experienced arm/hand swelling12. The trial 
included a small number of mastectomy patients (about 20%) and although the QOL results are 
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consistent with ours, they are not directly comparable since only 10% had chemotherapy and 20% 
had regional nodal irradiation in addition to breast/chest wall radiotherapy. The experience of 
breast/arm symptoms over 5 years represents chronic morbidity that has stronger association than 
cosmesis with long-term quality of life, making these important outcomes in clinical trials30. 
A  prospective study of 113 patients treated by mastectomy and 142 by breast conserving surgery 
using the EORTC QLQ-C30 and BR23 measures showed no overall difference in QOL between 
baseline and end of radiotherapy 31. However, its period of evaluation was confined to the duration 
of radiotherapy. The Moving Beyond Cancer psychosocial intervention trial studied the QOL of 558 
women with stage 1 and 2 breast cancer treated with surgery alone (breast conserving or 
mastectomy), surgery with radiation, or surgery followed by chemotherapy and radiation  over 1 
year, using SF-36 questionnaire. Similar to our study, physical and psychosocial function improved 
significantly over time. However, the measures of QOL differ from our study and details of 
chemotherapy regimes  and staging were not available in the absence of case record review27. A 
similar pattern of improvement in a range of symptoms and QOL measures in the first year post 
diagnosis was observed in a cohort study of 285 women with early breast cancer, treated with 
surgery (just >20% had mastectomy), adjuvant radiotherapy (74%) and systemic therapy in (just 
>30% of the patients)  33.  
Finally, we observed that younger women reported worse body image (if under 45) and anxiety 
problems (if under 70 years). This finding is supported by other breast cancer QOL studies, is 
concordant with clinical experience and emphasises the need for targeted psychological 
interventions in those women11,19. Younger women also reported higher general pain scores.  The 
reasons for this are not clear. The same finding was also reported in a randomised trial of 
radiotherapy after breast conserving therapy and in a population-based prospective study of more 
than 3000 patients following breast cancer surgery13,26. In the latter study, half the patients 
experienced moderate to severe pain, consistent with the range of reported pain in the literature 
from 25%-60%. The wide variation, as the authors suggest, may relate to varying definitions of pain, 
different methods of pain assessment and mix of surgery and adjuvant therapy. There is insufficient 
evidence to draw conclusions on each of the treatment related risk factors for pain. 
Reassuringly we observed no deterioration in symptoms and QOL scores over time. General pain did 
not improve with time, and this was not related to the use of aromatase inhibitors (data not shown). 
There is evidence of persistent pain in early breast cancer patients post-surgery, and our findings 
confirm these observations and call for better recognition of this problem in order to implement 
screening and patient support. 
Several strengths of SUPREMO trial should be mentioned. It is the largest post-mastectomy study 
which investigated a well-defined large population of patients treated by mastectomy, which was    
representative of women with early  ?ŝŶƚĞƌŵĞĚŝĂƚĞ-ƌŝƐŬ ? breast cancer in the UK. Individuals in the 
QOL study were recruited from almost all UK sites (only 10 out of 111 sites did not recruit any 
patients). The QOL study was multi-centre from across UK , representing a wide geographical range, 
thus minimising participating centre bias. The pre-specified QOL sample size was achieved and 
exceeded, strengthening the confidence in the findings. The trial was sufficiently large to allow 
explorative evaluation of the effects of age and multi-modality treatments. High levels of adherence 
to questionnaire completion over time were attained (>70%). In addition, guidelines on surgery, 
radiotherapy and systemic therapy were standardised in the protocol, so any variations in these 
treatment modalities between treatment arms are unlikely to influence the results.  
The main limitation of the QOL sub-study is not having a true pre-treatment baseline QOL 
assessment, as all patients were randomised following mastectomy. The relatively low QOL scores at 
the time of randomisation may be explained by the recent breast cancer diagnosis and the surgical 
procedure, and the subsequent improvement in almost all score, is to be expected.  We did not 
record QOL scores during or shortly after the allocated radiotherapy treatment, so any differences in 
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acute symptoms between the groups, which may predict later toxicity, have not been captured. In 
addition, since the main trial is ongoing and the loco-regional control and survival status of the 
patients in the QoL sub-study are not known to us, it is possible patients who had relapsed or died 
may have had different patterns of QOL. A larger proportion of participants in the QOL study 
received the radiotherapy as 45 Gy in 15 fractions (69%) compared to 52% in the main trial, where a 
larger proportion of 27% received 50 Gy in 25 fractions. This difference reflects the variations 
between the standard practice in UK and EORTC centres at the time of the trial. At this 2-year 
analysis we have not evaluated any effect of fractionation on the QoL outcomes. However, as the 
clinical significance of the increased chest wall symptoms in the radiotherapy group at 2 years may 
be relatively limited, we do not expect a major clinical impact of fractionation at this early time 
point. 
This paper presents a pre-planned analysis at 2 years post randomisation, with the main QOL 
analysis being planned at 5 years and QOL data to be collected for 10 years to capture late adverse 
events. Clearly our results are preliminary and we are therefore cautious in our interpretation. 
However, it is a reassuring that the loco-regional symptoms are minimal and do not impair global 
QOL and diminish over the initial 2 years of follow up.   Further analyses will be reported at 5 and 10 
years to determine if the trends at 2 years are sustained. It is possible that late radiotherapy toxicity 
not seen within the first two years (such as progressive chest wall fibrosis or increased cardiac 
toxicity due to the combination of radiotherapy and anthracycline-based chemotherapy) may be 
detected on longer term follow-up and should be captured in our 5 and 10 year analyses. However, 
we recognise that late cardiac toxicity from radiotherapy may occur beyond 10 years. 
The impact on PMRT on 10 year survival, the primary end-point of the main SUPREMO trial, will not 
be known before 2023. In the meantime, the decision to administer or omit PMRT can be considered 
 ?ƉƌĞĨĞƌĞŶĐĞƐĞŶƐŝƚŝǀĞ ? for patients in the SUPREMO trial risk category of 1-3 positive lymph nodes, as 
both options are legitimate. The patients will be in a better position to make a value judgment on 
what they consider relevant for them, given the data on various QOL domains presented in this 
report. Both physicians and patients may thus be helped when weighing up the individual estimates 
of possible benefits of radiotherapy against the impact of PMRT on toxicity and QOL endpoints. This 
will support the application of informed shared decision-making, as recommended by the recent 
North American guidelines, even before the main trial outcome becomes available 7. 
In conclusion, chest wall radiotherapy led to more chest wall symptoms up to 2 years post-
randomisation, but the difference is small and unlikely to be clinically significant. There was no 
impact on the other pre-specified QOL domains.  However, the trend for worse QOL scores for 
anxiety, body image and chest wall symptoms in younger women irrespective of irradiation warrants 
further investigation. Longer term follow-up at 5 and 10 years will be needed to see if these early 
trends in quality of life are sustained. 
Contributors 
GV LW SW JMD IHK NSR were involved in the study design. IHK NSR oversaw the trial and GV LW SW 
JMD were members of the trial management group. JMD JL MH JC IHK NSR recruited patients. LW 
GV SW IHK NSR did the data analysis. GV SW JMD JL MH JC IHK NSR interpreted the data. GV LW SW 
IHK NSR wrote the paper. JMD JL MH JC reviewed the drafts. GV IHK NSR gave final approval of the 
manuscript.  
 
Declarations of interest 
GV has received research grants from National Institute of Health Research (NIHR), Cancer Research 
UK, Yorkshire Cancer Research and personal fees from Roche, Novartis, and Eisai.   SW has received 
research grant from NIHR. JMD has received personal fees from Pfizer. IHK has received research 
 13 
funding from NIHR. NSR has received research grants from the Dutch Cancer Society and EORTC. The 
other authors declare no competing interests. 
 
Acknowledgments 
We thank the patients, their relatives and treating clinicians, and the hospitals who agreed to 
participate in this study. The list of contributors from UK participating centres is provided in an 
online appendix. 
We thank Medical Research Council (MRC)(EME 09/800/31), European Organisation for Research 
and Treatment of Cancer (EORTC), Cancer Australia, The Dutch Cancer Society, the Trustees of the 
Hong Kong and Shanghai Banking Corporation (HSBC) for funding the study.  
We wish to acknowledge the support of the staff at The Information and Statistical Division at 
National Services Scotland and specifically Kathleen Riddle Principal Trial Manager, Penny Hopwood 
(The Christie Hospital, Manchester) initial chief Investigator for the QOL sub-study (who has 
subsequently retired), the Scottish Cancer Trials Breast Group and Breast International Group (BIG) 
under whose auspices the trial was run (Chair: Dr Iain MacPherson), the Trial Management Group, 
the Trial Steering Committee (Chair Professor Barry Hancock, University of Sheffield), and the Data 
Monitoring and Ethical Committee (Chair Professor Chris Frost, University of London). 
We also thank the National Institute for Health Research Cancer Research Networks in England and 
their equivalent NHS R&D-ĨƵŶĚĞĚŶĞƚǁŽƌŬƐ ŝŶ^ĐŽƚůĂŶĚ ?tĂůĞƐ ?ĂŶĚEŽƌƚŚĞƌŶ /ƌĞůĂŶĚ ĨŽƌ  “ŝŶ-ŬŝŶĚ ?
support. 
 
 
 
 
 
 
 
  
 14 
References 
1. Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, 
Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an 
analysis of population-based cancer registry data. Lancet 2011; 377(9760): 127-38. 
2. Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, investigators PI. Breast-conserving 
surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME 
II): a randomised controlled trial. Lancet Oncol 2015; 16(3): 266-73. 
3. Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-Gene Signature as an Aid to Treatment 
Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375(8): 717-29. 
4. Koch L, Jansen L, Herrmann A, et al. Quality of life in long-term breast cancer survivors - a 
10-year longitudinal population-based study. Acta Oncol 2013; 52(6): 1119-28. 
5. Russell NS, Kunkler IH, van Tienhoven G. Determining the indications for post mastectomy 
radiotherapy: moving from 20th century clinical staging to 21st century biological criteria. Ann Oncol 
2015; 26(6): 1043-4. 
6. Early Breast Cancer Trial;lists' Collaborative Group (EBCTCG), McGale P, Taylor C, et al. Effect 
of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast 
cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. 
Lancet 2014; 383(9935): 2127-35. 
7. Recht A, Comen EA, Fine RE, et al. Postmastectomy Radiotherapy: An American Society of 
Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology 
Focused Guideline Update. J Clin Oncol 2016; 34(36): 4431-42. 
8. Shapiro CL, Hardenbergh PH, Gelman R, et al. Cardiac effects of adjuvant doxorubicin and 
radiation therapy in breast cancer patients. J Clin Oncol 1998; 16(11): 3493-501. 
9. Kunkler IH, Canney P, van Tienhoven G, Russell NS, MRC/EORTC (BIG2-04) SUPREMO Trial 
Management Group. Elucidating the role of chest wall irradiation in 'intermediate-risk' breast 
cancer: the MRC/EORTC SUPREMO trial. Clin Oncol (R Coll Radiol) 2008; 20(1): 31-4. 
10. Eccles SA, Aboagye EO, Ali S, et al. Critical research gaps and translational priorities for the 
successful prevention and treatment of breast cancer. Breast Cancer Res 2013; 15(5): R92. 
11. Hopwood P, Haviland J, Mills J, Sumo G, J MB, Group STM. The impact of age and clinical 
factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START 
Trial (Standardisation of Breast Radiotherapy Trial). Breast 2007; 16(3): 241-51. 
12. Hopwood P, Haviland JS, Sumo G, et al. Comparison of patient-reported breast, arm, and 
shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in 
the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncol 2010; 11(3): 
231-40. 
13. Pignol JP, Truong P, Rakovitch E, Sattler MG, Whelan TJ, Olivotto IA. Ten years results of the 
Canadian breast intensity modulated radiation therapy (IMRT) randomized controlled trial. 
Radiother Oncol 2016; 121(3): 414-9. 
14. Whelan TJ, Levine M, Julian J, Kirkbride P, Skingley P. The effects of radiation therapy on 
quality of life of women with breast carcinoma: results of a randomized trial. Ontario Clinical 
Oncology Group. Cancer 2000; 88(10): 2260-6. 
15. Williams LJ, Kunkler IH, King CC, Jack W, van der Pol M. A randomised controlled trial of post-
operative radiotherapy following breast-conserving surgery in a minimum-risk population. Quality of 
life at 5 years in the PRIME trial. Health Technol Assess 2011; 15(12): i-xi, 1-57. 
16. Howes BH, Watson DI, Xu C, Fosh B, Canepa M, Dean NR. Quality of life following total 
mastectomy with and without reconstruction versus breast-conserving surgery for breast cancer: A 
case-controlled cohort study. J Plast Reconstr Aesthet Surg 2016; 69(9): 1184-91. 
17. Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-
reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg 2009; 124(2): 345-
53. 
 15 
18. Pusic AL, Matros E, Fine N, et al. Patient-Reported Outcomes 1 Year After Immediate Breast 
Reconstruction: Results of the Mastectomy Reconstruction Outcomes Consortium Study. J Clin Oncol 
2017: JCO2016699561. 
19. Santosa KB, Qi J, Kim HM, Hamill JB, Pusic AL, Wilkins EG. Effect of Patient Age on Outcomes 
in Breast Reconstruction: Results from a Multicenter Prospective Study. J Am Coll Surg 2016; 223(6): 
745-54. 
20. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and 
Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in 
oncology. J Natl Cancer Inst 1993; 85(5): 365-76. 
21. Sprangers MA, Groenvold M, Arraras JI, et al. The European Organization for Research and 
Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a 
three-country field study. J Clin Oncol 1996; 14(10): 2756-68. 
22. Hopwood P, Fletcher I, Lee A, Al Ghazal S. A body image scale for use with cancer patients. 
Eur J Cancer 2001; 37(2): 189-97. 
23. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 
1983; 67(6): 361-70. 
24. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35(11): 1095-108. 
25. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of 
life: the remarkable universality of half a standard deviation. Med Care 2003; 41(5): 582-92. 
26. Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors 
associated with persistent pain following breast cancer surgery. JAMA 2009; 302(18): 1985-92. 
27. Ganz PA, Kwan L, Stanton AL, Bower JE, Belin TR. Physical and psychosocial recovery in the 
year after primary treatment of breast cancer. J Clin Oncol 2011; 29(9): 1101-9. 
28. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a 
positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, 
open-label, phase 3 non-inferiority trial. Lancet Oncol 2014; 15(12): 1303-10. 
29. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based 
guidelines for determination of sample size and interpretation of the European Organisation for the 
Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 2011; 29(1): 
89-96. 
30. Casso D, Buist DS, Taplin S. Quality of life of 5-10 year breast cancer survivors diagnosed 
between age 40 and 49. Health Qual Life Outcomes 2004; 2: 25. 
31. Munshi A, Dutta D, Kakkar S, et al. Comparison of early quality of life in patients treated with 
radiotherapy following mastectomy or breast conservation therapy: a prospective study. Radiother 
Oncol 2010; 97(2): 288-93. 
32. Rim CH, Ahn SJ, Kim JH, et al. An assessment of quality of life for early phase after adjuvant 
radiotherapy in breast cancer survivors: a Korean multicenter survey (KROG 14-09). Health Qual Life 
Outcomes 2017; 15(1): 96. 
33. Hsu T, Ennis M, Hood N, Graham M, Goodwin PJ. Quality of life in long-term breast cancer 
survivors. J Clin Oncol 2013; 31(28): 3540-8. 
 
  
 16 
Tables 
dĂďůĞ ? ?WĂƚŝĞŶƚƐ ?ĚĞŵŽŐƌĂƉŚŝĐĂŶĚĐůŝŶŝĐĂůĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ 
Patient demographic and clinical 
characteristics 
QOL study Full trial 
 No RT RT No RT RT 
Demographic 476 471 835 853 
Age (mean and SD) 56·3 (11·3) 55·8 (10·8) 55·9 (11·2) 55·8 (11·3) 
Menopausal status (number, %) 
Pre-menopausal 
Peri-menopausal 
Post-menopausal 
Not known 
 
126 (26·5) 
43 (9·0) 
290 (60·9) 
17 (3·6) 
 
135 (28·7) 
52 (11·0) 
268 (56·9) 
16 (3·4) 
 
246 (29·5) 
68 (8·1) 
483 (57·8) 
38 (4·6) 
 
243 (28·5) 
85 (10·0) 
475 (55·7) 
50 (5·9) 
     
Tumour characteristics     
Side of primary tumour (number, %) 
Left 
Right 
 
238 (51·2) 
227 (48·8) 
 
216 (47·8) 
236 (52·2) 
 
398 (50·1) 
396 (49·9) 
 
407 (51·3) 
387 (48·7) 
Tumour size (number, %) 
ч ?Đŵ 
2·1-5 cm 
>5 cm 
Unknown 
 
132 (27·7) 
337 (70·8) 
5 (1·1) 
2 (0·4) 
 
138 (29·3) 
332 (70·5) 
1 (0·2) 
0 
 
249 (29·8) 
566 (67·8) 
4 (0·5) 
16 (1·9) 
 
261 (30·6) 
566 (66·4) 
4 (0·5) 
22 (2·6) 
Tumour grade (number, %) 
I 
II 
III 
Not specified 
 
20 (4·2) 
190 (39·9) 
262 (55·0) 
4 (0·8) 
 
23 (4·9) 
195 (41·4) 
250 (53·1) 
3 (0·6) 
 
46 (5·5) 
335 (40·1) 
432 (51·7) 
22 (2·6) 
 
57 (6·7) 
333 (39·0) 
432 (50·6) 
31 (3·6) 
Histological type (number, %) 
Ductal 
Lobular 
Mucinous 
Tubular 
Adenocarcinoma 
Other  
 
372 (78·5) 
58 (12·2) 
5 (1·1) 
1 (0·2) 
3 (0·6) 
35 (7·4) 
 
374 (79·4) 
49 (10·4) 
1 (0·2) 
3 (0·6) 
5 (1·1) 
39 (8·3) 
 
641 (78·2) 
95 (11·6) 
7 (0·9) 
4 (0·5) 
16 (2·0) 
57 (7·0) 
 
661 (79·5) 
89 (10·7) 
1 (0·1) 
4 (0·5) 
13 (1·6) 
63 (7·6) 
Molecular markers  W (number, %) 
ER+/PR+ 
ER+/PR- 
ER-/PR+ 
ER-/PR- 
ER+/PR unknown 
ER-/PR unknown 
 
Her2 positive 
Her2 negative 
Not measured 
 
218 (46·8) 
48 (10·3) 
5 (1·1) 
87 (18·7) 
96 (20·6) 
12 (2·6) 
 
140 (29·7) 
286 (60·7) 
45 (9·6) 
 
 
217 (46·7) 
48 (10·3) 
0 (0) 
93 (20·0) 
100 (21·5) 
7 (1·5) 
 
145(31·1) 
281 (60·2) 
41 (8·8) 
 
 
417 (51·5) 
83 (10·3) 
8 (1·0) 
156 (19·3) 
131 (16·2) 
15 (1·9) 
 
273 (33·5) 
475 (58·2) 
68 (8·3) 
 
 
416 (50·6) 
99 (12·0) 
3 (0·4) 
162 (19·7) 
132 (16·0) 
11 (1·3) 
 
269 (32·5) 
469 (59·9) 
63 (7·6) 
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Patient demographic and clinical 
characteristics 
QOL study Full trial 
 No RT RT No RT RT 
Axillary Nodes (number, %) 
0 (negative) 
1- 
2- 
3- 
Not known 
 
130 (27·3) 
180 (37·8) 
101 (21·2) 
63(13·4) 
2 (0·4) 
 
113 (24·0) 
199 (42·3) 
111 (23·6) 
48 (10·2) 
0 
 
219 (26·2) 
316 (37·8) 
178 (21·3) 
107 (12·8) 
15 (1·8) 
 
212 (24·9) 
338 (39·6) 
194 (22·7) 
88 (10·3) 
21 (2·5) 
     
Treatment     
Breast Surgery (number, %) 
Mastectomy only 
Immediate breast reconstruction 
prior to RT 
Late breast reconstruction  
 
371 (77·9) 
50 (10·5) 
 
55 (11·6) 
 
359 (76·2) 
61 (13·0) 
 
51 (10·8) 
 
653 (78·2) 
85 (10·2) 
 
97 (11·6) 
 
669 (78·4) 
97 (11·4) 
 
87 (10·2) 
     
Axillary surgery (number, %) 
SLN / node sampling 
SLN plus ANC (Axillary node 
clearance) 
ANC (without SLN) 
 
131 (27·9) 
138 (29·4) 
 
201 (42·8) 
 
108 (22·9) 
124 (26·3) 
 
239 (50·7) 
 
207 (25·5) 
229 (28·2) 
 
377 (46·4) 
 
189 (22·8) 
224 (27·0) 
 
417 (50·2) 
Systemic treatment (number Yes, %) 
Neo-adjuvant chemotherapy1  
Adjuvant chemotherapy 
Anthracyclines 
Taxanes 
Trastuzumab 
 
Endocrine therapy (number Yes, %) 
Neo-adjuvant 
Adjuvant 
Aromatase inhibitor 
Tamoxifen 
Other  
 
1/173 (0·58) 
395 (83·0) 
372/395(94·2) 
197/395(49·9) 
91/454 (20·5) 
 
 
2/200 (1·0) 
349 (73·3) 
173/349(49·6) 
174/349(49·9) 
2/349 (0·6) 
 
7/173 (4·1) 
401 (85·1) 
379/401(94·5) 
207/401(51·6) 
92/460 (20·0) 
 
 
8/206 (3·9) 
363 (77·1) 
195/363(53·7) 
168/363(46·3) 
0/363 (0) 
 
7/243 (2·9) 
682 (81·7) 
636/682(93·3) 
392/682(57·5) 
150/782(19·2) 
 
 
10/288 (3·5) 
598 (71·6) 
275/598(46·0) 
319/598(53·3) 
4/598 (0·8) 
 
16/269 (6·0) 
709 (83·1) 
655/709(92·4) 
418/709(59·0) 
166/806(20·6) 
 
 
17/316 (5·4) 
631 (73·9) 
314/631(49·8) 
314/631(49·8) 
3/631 (0·5) 
1 Only recorded in protocol v29 onwards 
ER- estrogen receptor; PR  W progesteron receptor; SLN- sentinel lymph node(s) procedure; ANC  W 
axillary node clearance 
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Table 2. Quality of Life (QOL) scores (Standard Deviations, SD) at baseline, year 1 and year 2 follow-
up 
 
QoL measure Baseline Year 1 Year 2 
Mean (SD) No RT 
(n=476) 
RT (n=471) No RT 
(n=388) 
RT (n=388) No RT 
(n=350) 
RT (n=367) 
Age at 
randomisation 
56·3 (11·3) 55·8 (10·8) 56·5 (10·9) 56·1 (10·4) 56·8 (10·9) 56·1 (10·4) 
       
Primary endpoints      
EORTC QLQ-C30       
Global 
Health/QoL* 
60·9 (21·6) 60·4 (20·8) 70·0 (20·5) 70·0 (19·8) 70·2 (20·5) 71·8 (20·1) 
Fatigue** 41·6 (25·2) 43·0 (26·1) 30·3 (23·2) 31·0 (24·1) 29·2 (24·2) 27·5 (23·8) 
Physical 
Functioning* 
79·6 (20·2) 80·1 (19·6) 81·9 (19·0) 81·1 (19·1) 82·0 (18·6) 82·1 (19·3) 
       
EORTC QLQ-BR23       
Arm symptoms** 20·3 (20·5) 21·2 (21·7) 21·2 (21·7) 22·4 (22·0) 20·7 (21·4) 19·9 (20·3) 
Chest wall/breast 
symptoms** 
17·3 (17·0) 18·1 (18·3) 13·1 (16·3) 16·1 (16·7) 11·6 (14·6) 14·1 (15·8) 
       
Body Image 
Scale** 
10·3 (7·9) 11·1 (8·2) 9·3 (7·6) 9·8 (7·7) 8·1 (6·7) 8·7 (7·4) 
       
Hospital Anxiety and 
Depression Scale (HADS) 
     
Anxiety 6·2 (4·4) 6·1 (4·3) 6·8 (4·7) 6·5 (4·4) 6·3 (4·3) 6·5 (4·4) 
Depression 4·5 (3·7) 4·6 (3·7) 4·2 (3·7) 4·2 (3·8) 4·0 (3·5) 4·2 (3·9) 
       
Secondary endpoints      
EORTC QLQ-C30       
Role Functioning * 65·2 (30·9) 63·0 (30·5) 79·3 (27·1) 78·8 (25·8) 79·7 (27·6) 81·0 (26·9) 
Social Functioning 
* 
65·5 (28·7) 64·0 (29·1) 79·4 (25·6) 80·3 (24·7) 80·5 (26·1) 83·9 (25·2) 
Pain** 22·6 (26·5) 24·8 (27·9) 21·7 (26·8) 23·7 (26·5) 23·4 (27·3) 21·6 (25·9) 
Nausea 
Vomiting** 
11·2 (17·6) 11·5 (20·1) 5·3 (13·1) 5·1 (12·1) 4·6 (12·2) 5·1 (13·6) 
       
EORTC QLQ-BR23       
Sexual 
Functioning* 
11·5 (18·1) 
n=455 
12·5 (19·0) 
n=459 
15·7 (20·5) 
n=372 
17·6 (21·2) 
n=374 
16·3 (21·7) 
n=325 
18·1 (22·3) 
n=353 
       
Exploratory variables      
EORTC QLQ-C30       
Emotional 
Functioning* 
74·7 (22·6) 73·7 (24·4) 75·2 (23·6) 75·2 (22·3) 77·3 (22·5) 75·7 (23·3) 
Cognitive 
Functioning* 
77·1 (23·4) 75·0 (26·1) 78·2 (22·8) 78·2 (22·9) 78·6 (22·8) 78·2 (23·8) 
Dyspnoea** 20·8 (26·4) 20·0 (26·1) 14·6 (23·5) 14·8 (23·0) 14·3 (23·2) 13·4 (22·5) 
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QoL measure Baseline Year 1 Year 2 
Mean (SD) No RT 
(n=476) 
RT (n=471) No RT 
(n=388) 
RT (n=388) No RT 
(n=350) 
RT (n=367) 
Insomnia** 36·3 (31·1) 37·2 (32·8) 36·4 (33·5) 38·5 (32·8) 33·9 (31·9) 35·0 (30·5) 
Appetite loss** 20·7 (28·9) 19·2 (27·9) 9·5 (19·8) 8·7 (18·5) 9·1 (19·9) 9·0 (20·7) 
Constipation** 18·2 (26·3) 17·0 (26·1) 14·9 (24·5) 14·5 (24·1) 17·6 (27·7) 14·5 (24·3) 
Diarrhoea** 11·9 (20·7) 12·1 (23·8) 7·6 (17·5) 8·4 (18·7) 5·4 (15·1) 8·7 (19·1) 
Financial 
difficulties** 
23·9 (33·1) 23·2 (31·7) 15·8 (28·5) 17·1 (27·8) 14·1 (27·0) 13·8 (26·6) 
       
EORTC QLQ-BR23       
Sexual 
enjoyment* 
49·9 (26·9) 
n=121 
53·0 (29·1) 
n=132 
54·4 (28·3) 
n=136 
56·5 (26·5) 
n=144 
52·5 (26·1) 
n=115 
56·6 (28·8) 
n=136 
Future 
perspective** 
45·8 (31·2) 46·4 (32·8) 49·8 (32·3) 50·9 (31·6) 54·4 (30·1) 54·1 (30·9) 
Systemic therapy 
side-effects** 
34·8 (23·1) 35·2 (22·7) 19·3 (15·2) 19·6 (15·6) 18·6 (14·9) 18·3 (15·0) 
Hair loss** 29·6 (37·5) 31·7 (39·3) 6·2 (20·4) 6·4 (21·8) 3·8 (20·7) 4·9 (17·1) 
       
EQ-5D-3L*** 0·74 (0·22) 0·74 (0·22) 0·75 (0·25) 0·75 (0·24) 0·76 (0·24) 0·77 (0·22) 
 
 
*EORTC QLQ-C30 Functional scores- range 0-100 (higher score = good functioning) 
** EORTC QLQ-C30 Symptom scores  W range 0-100 (higher score = worse symptoms) 
*** EQ-5D-3L score-range 0-1. 
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Table 3. Mixed effects models (fixed effects) for the primary QOL outcomes 
 
Outcome Model variable Estimate of 
effects 
95% CI p 
Global 
QOL (C30) 
Baseline score 
Age- ref* >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT  Wref no RT 
-0·57 
- 
1·12 
3·25 
3·54 
0·75 
1·39 
-0·63, -0·52 
- 
-3·45, 5·78 
-0·62, 7·12 
-0·28, 7·36 
-0·46, 1·97 
-0·92, 3·71 
<0·0001 
- 
0·64 
0·10 
0·07 
0·23 
0·24 
 Adjusted 
mean of 
 ?ĐŚĂŶŐĞ
ƐĐŽƌĞƐ ?**  
95% CI p-value*** 
   
RT 
No RT 
8·63 
7·23 
6·86, 10·40 
5·46, 9·01 
<0·0001 
<0·0001 
Fatigue 
(C30) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
Immediate 
reconstruction 
Ref no recon 
RT  Wref no RT 
-0·59 
- 
-2·41 
-4·14 
-3·13 
-1·83 
5·32 
 
 
-1·93 
-0·65, -0·54 
- 
-8·07, 3·26 
-8·84, 0·56 
-7·73, 1·47 
-3·20, -0·46 
0·94, 9·69 
 
 
-4·70, 0·84 
<0·0001 
- 
0·40 
0·08 
0·18 
0·009 
0·017 
 
0·17 
RT 
No RT 
-9·54 
-7·61 
-12·19, -6·89 
-10·35, -4·87 
<0·0001 
<0·0001 
Physical 
function 
(C30) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT  Wref no RT 
-0·41 
- 
7·91 
7·06 
4·29 
0·20 
-0·17 
-0·46, -0·35 
- 
3·94, 11·87 
3·80, 10·32 
1·06, 7·51 
-0·68, 1·08 
-2·13, 1·79 
<0·0001 
- 
<0·0001 
<0·0001 
0·009 
0·65 
0·87 
RT 
No RT 
-0·02 
0·14 
-1·53, 1·48 
-1·36, 1·65 
0·97 
0·85 
Chest wall 
symptoms 
(BR23) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
Chemo-ref no chemo 
RT  Wref no RT 
-0·57 
- 
4·49 
1·88 
2·36 
-1·34 
3·74 
2·17 
-0·62, -0·52 
- 
0·59, 8·39 
-1·46, 5·22 
-0·79, 5·51 
-2·36, -0·31 
0·87, 6·61 
0·40, 3·94 
<0·0001 
- 
0·02 
0·26 
0·14 
0·010 
0·011 
0·016 
RT -3·13 -4·74, -1·51 0·0002 
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No RT -5·30 -6·88, -3·71 <0·0001 
Arm and 
shoulder 
symptoms 
(BR23) 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
Chemo-ref no chemo 
RT  Wref no RT 
-0·51 
- 
0·86 
2·89 
2·76 
-0·93 
6·15 
-0·53 
-0·57, 0·45 
- 
-4·42, 6·14 
-1·64, 7·41 
-1·51, 7·03 
-2·22, 0·37 
2·26, 10·05 
-2·92, 1·86 
<0·0001 
- 
0·74 
0·21 
0·20 
0·16 
0·002 
0·66 
RT 
No RT 
-1·44 
-0·91 
-3·63, 0·75 
-3·06, 1·24 
0·19 
0·40 
Body 
Image 
Scale  
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT  Wref no RT 
-0·39 
- 
1·96 
1·39 
0·83 
-0·91 
-0·09 
-0·43, 0·34 
- 
0·53, 3·39 
0·20, 2·58 
-0·33, 1·99 
-1·28, -0·55 
-0·79, 0·61 
<0·0001 
- 
0·007 
0·022 
0·15 
<0·0001 
0·79 
RT 
No RT 
-1·36 
-1·27 
-1·90, -0·83 
-1·81, -0·73 
<0·0001 
<0·0001 
HADS-
Anxiety 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT  Wref no RT 
-0·30 
- 
1·69 
1·36 
1·21 
-0·05 
-0·16 
-0·35, -0·25 
- 
0·86, 2·53 
0·67, 2·06 
0·53, 1·90 
-0·29, 0·18 
-0·57, 0·25 
<0·0001 
- 
<0·0001 
0·0001 
0·0005 
0·66 
0·44 
RT 
No RT 
0·44 
0·60 
0·13, 0·76 
0·29, 0·92 
0·006 
0·0002 
HADS- 
Depression 
Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT  Wref no RT 
-0·35 
- 
0·07 
-0·05 
-0·04 
0·02 
-0·14 
-0·41, 0·30 
- 
-0·73, 0·87 
-0·72, 0·61 
-0·69, 0·62 
-0·16, 0·20 
0·54, 0·25 
<0·0001 
- 
0·87 
0·88 
0·91 
0·94 
0·48 
RT 
No RT 
-0·19 
0·05 
-0·50, 0·11 
-0·35, 0·25 
0·21 
0·75 
Pain (C30) Baseline score 
Age- ref >70 
- <45 
- 45-54 
- 55-69 
Visit-ref year1  
RT  Wref no RT 
-0·51 
- 
-0·18 
2·76 
2·18 
0·31 
-0·65 
-0·57, -0·46 
- 
-6·16, 5·80 
-2·17, 7·69 
-2·70, 7·06 
-1·29, 1·91 
-3·62, 2·33 
<0·0001 
- 
0·95 
0·27 
0·38 
0·70 
0·67 
RT 
No RT 
0·28 
0·93 
-1·99, 2·56 
-1·35, 3·20 
0·81 
0·42 
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* ref =reference category in the mixed-effects models 
** shaded cells - the adjusted mean for the individual arms is the mean ŽĨƚŚĞ ?ĐŚĂŶŐĞƐĐŽƌĞƐ ? ?
(defined as change from baseline to year 1 and from baseline to year 2) in each of the treatment 
groups, adjusted for baseline score, visit, and age;  
***p values  - whether each of the means ŽĨƚŚĞ ?ĐŚĂŶŐĞƐĐŽƌĞƐ ? within each individual arm is 
significantly different from zero (i.e., improvement or deterioration in scores from baseline) 
 
